MiniMed Group (NASDAQ:MMED) Price Target Raised to $26.00

MiniMed Group (NASDAQ:MMED) had its target price raised by Wells Fargo & Company from $22.00 to $26.00 in a research report sent to investors on Wednesday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

MMED has been the topic of several other reports. BTIG Research raised their target price on MiniMed Group from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings raised MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Benchmark restated a “buy” rating on shares of MiniMed Group in a research report on Thursday, June 4th. Bank of America raised their price objective on shares of MiniMed Group from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $16.00 target price on shares of MiniMed Group in a report on Thursday, June 4th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $23.77.

MiniMed Group Stock Performance

NASDAQ:MMED opened at $23.28 on Wednesday. The firm has a fifty day simple moving average of $18.21. The stock has a market capitalization of $6.55 billion and a price-to-earnings ratio of -34.24. MiniMed Group has a one year low of $10.65 and a one year high of $24.43.

MiniMed Group (NASDAQ:MMED) last released its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. The business’s revenue was up 15.6% on a year-over-year basis. On average, research analysts predict that MiniMed Group will post 0.7 EPS for the current year.

Hedge Funds Weigh In On MiniMed Group

Several institutional investors and hedge funds have recently modified their holdings of MMED. J. Goldman & Co LP purchased a new position in MiniMed Group during the second quarter worth approximately $12,412,000. Freestone Grove Partners LP purchased a new stake in shares of MiniMed Group in the second quarter valued at approximately $1,745,000. Deutsche Bank AG acquired a new position in shares of MiniMed Group during the 2nd quarter worth approximately $420,000. BlackRock Inc. raised its stake in shares of MiniMed Group by 7,527.5% during the 2nd quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock worth $29,848,000 after buying an additional 1,970,314 shares during the period. Finally, Punch & Associates Investment Management Inc. purchased a new position in shares of MiniMed Group during the 2nd quarter valued at approximately $292,000.

MiniMed Group News Summary

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Analysts see further upside: Citigroup and Wells Fargo issued forecasts calling for strong price appreciation, while analysts at Mizuho, UBS Group, Bank of America and BTIG Research also said MiniMed’s share price is expected to rise. The cluster of bullish views may support investor confidence and buying interest. Citigroup forecast Wells Fargo forecast Mizuho analyst view UBS analyst view Bank of America analyst view BTIG analyst view
• Positive Sentiment: New products are driving optimism: A recent product introduction helped lift MiniMed’s top line, with further launches scheduled over the coming months. Investors appear to be viewing the product pipeline as a potential source of sustained growth. Why MiniMed stock was soaring
• Positive Sentiment: Operational momentum is improving: Coverage highlights recurring revenue streams, regulatory progress and a strong beginning to fiscal 2027, reinforcing the case for more predictable growth. Recurring revenues and product cycle Fiscal 2027 progress
• Neutral Sentiment: Morgan Stanley raised its target: The firm increased its target from $19 to $21 and maintained an “overweight” rating. However, the new target remains below the referenced recent trading level, suggesting that some expected gains may already be reflected in the valuation.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.